Amniotics AB (OSTO:AMNI) Gross-Profit-to-Asset % : 0.00% (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Amniotics AB Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. Amniotics AB's annualized Gross Profit for the quarter that ended in Dec. 2023 was kr0.00 Mil. Amniotics AB's average Total Assets over the quarter that ended in Dec. 2023 was kr24.99 Mil. Therefore, Amniotics AB's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2023 was 0.00%.

Amniotics AB Gross-Profit-to-Asset % Historical Data

The historical data trend for Amniotics AB's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Amniotics AB Gross-Profit-to-Asset % Chart

Amniotics AB Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Gross-Profit-to-Asset %

Amniotics AB Quarterly Data
	Dec19	Mar20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Jun23	Sep23	Dec23
Gross-Profit-to-Asset %	Get a 7-Day Free Trial										-	-	-	-	-

Competitive Comparison of Amniotics AB's Gross-Profit-to-Asset %

For the Biotechnology subindustry, Amniotics AB's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Amniotics AB's Gross-Profit-to-Asset % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Amniotics AB's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where Amniotics AB's Gross-Profit-to-Asset % falls into.

Amniotics AB Gross-Profit-to-Asset % Calculation

Amniotics AB's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Dec. 2023 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (A: Dec. 2023 )	/	( (Total Assets (A: Dec. 2022 )	+	Total Assets (A: Dec. 2023 ))	/ count )
	=	0	/	( (28.918	+	26.086)	/ 2 )
	=	0	/	27.502
	=	0.00 %

Amniotics AB's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2023 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (Q: Dec. 2023 )	/	( (Total Assets (Q: Sep. 2023 )	+	Total Assets (Q: Dec. 2023 ))	/ count )
	=	0	/	( (23.891	+	26.086)	/ 2 )
	=	0	/	24.9885
	=	0.00 %

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is four times the quarterly (Dec. 2023) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.

Amniotics AB Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of Amniotics AB's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.

Amniotics AB (OSTO:AMNI) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Amniotics AB (OSTO:AMNI) » Definitions » Gross-Profit-to-Asset %

Comparable Companies

Traded in Other Exchanges

66J:Germany

Address

Scheelevagen 2, Lund, SWE, 223 63

Website

https://www.amniotics.com

Amniotics AB is a biopharma company focusing on mesenchymal stem cells from amniotic fluid. It provides a novel platform for the production of medically superior mesenchymal stem cells including ethical and medically sound bio-banking opportunities for the newborn.